Angel Rodríguez

发表

Early Discontinuation and Restart of Insulin in the Treatment of Type 2 Diabetes Mellitus

H. Ascher-Svanum, M. Lage, M. Treglia, 2014, Diabetes Therapy.

Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.

P. Norwood, Angel Rodriguez, Y. Onishi, 2022, JAMA.

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial

B. Ludvik, F. Giorgino, J. Frias, 2021, The Lancet.

The application of atherogenic dyslipidaemia consensus recommendations in the primary care setting. DAT-AP study.

Angel Rodriguez, Adalberto Serrano Cumplido, J. Núñez-Cortés, 2017, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

Relationships between obesity, glycemic control, and cardiovascular risk factors: a pooled analysis of cross-sectional data from Spanish patients with type 2 diabetes in the preinsulin stage

J. Salvador, J. Reviriego, J. Ascaso, 2014, BMC Cardiovascular Disorders.

Predictors of Change in Adherence Status from 1 Year to the Next Among Patients with Type 2 Diabetes Mellitus on Oral Antidiabetes Drugs

H. Fu, H. Ascher-Svanum, A. Ali, 2016, Journal of managed care & specialty pharmacy.

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Dovepress

M. Serrano-Ríos, J. Reviriego, Angel Rodriguez, 2010 .

Risk factors associated with metabolic syndrome in type 2 diabetes mellitus patients according to World Health Organization, Third Report National Cholesterol Education Program, and International Diabetes Federation definitions

M. Serrano-Ríos, J. Reviriego, Angel Rodriguez, 2010, Diabetes, metabolic syndrome and obesity : targets and therapy.

Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis

B. Hoogwerf, A. Lincoff, Y. Qu, 2016, Cardiovascular Diabetology.

Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.

K. Cusi, A. Gastaldelli, Angel Rodriguez, 2022, The lancet. Diabetes & endocrinology.

Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study

J. Reviriego, Angel Rodriguez, N. Vlachogiannis, 2011 .

80-LB: Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Is Effective and Safe When Added to Basal Insulin for Treatment of Type 2 Diabetes (SURPASS-5)

P. Norwood, Angel Rodriguez, Y. Onishi, 2021, Diabetes.

Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease

R. Roussel, Angel Rodriguez, Carole Salaun-Martin, 2015, Advances in Therapy.

Efficacy and safety of a premixed versus a basal-plus insulin regimen as intensification for type 2 diabetes by timing of the main meal

F. Tinahones, J. Gross, Sanjiv Shah, 2016, Current medical research and opinion.

Clinical course after five years of insulin therapy in patients with type 2 diabetes in Spain: results of the EDIN study.

J. Reviriego, Angel Rodriguez, S. Tofé, 2014, Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion.

Comparison of insulin intensification strategies with insulin lispro low mixture twice daily versus basal insulin glargine and prandial insulin lispro once daily in East Asian and Caucasian patients with type 2 diabetes mellitus

C. Chung, Zhiguang Zhou, I. Jeong, 2017, Journal of diabetes.

Insulin lispro low mixture twice daily vs basal insulin glargine once daily and prandial insulin lispro once daily as insulin intensification strategies in patients with type 2 diabetes: Latin American subpopulation analysis of a randomized trial

J. Gross, G. Sposetti, Angel Rodriguez, 2015, Diabetology & Metabolic Syndrome.

Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: A post hoc assessment of the SURPASS clinical trial programme

G. Umpierrez, F. Giorgino, C. Nicolay, 2023, Diabetes, obesity & metabolism.

A new high-absorption-rate Paracetamol 500-mg formulation: a comparative bioavailability study in healthy volunteers.

E. Vargas, Angel Rodriguez, A. Portolés, 2003, Current therapeutic research, clinical and experimental.

Clinical evaluation of combined therapy for type 2 diabetes

J. Reviriego, Angel Rodriguez, S. Tofé, 2010, Current medical research and opinion.

729-P: Relationship between Body Weight Change and Glycemic Control with Tirzepatide Treatment in People with Type 2 Diabetes

G. Umpierrez, F. Giorgino, S. Pedersen, 2022, Diabetes.

Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.

R. Bergenstal, T. Battelino, Angel Rodriguez, 2022, The lancet. Diabetes & endocrinology.

Clinical Characteristics and Degree of Glycemic and Cardiovascular Risk Factor Control in Patients with Type 1 Diabetes in Catalonia (Spain)

D. Mauricio, E. Ortega, A. Goday, 2021, Journal of clinical medicine.

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Dovepress

M. Serrano-Ríos, J. Reviriego, H. Delgado-cohen, 2010 .